🚀 Exciting Announcement!
February 25, 2025
Ash Alavijeh,
Pharmidex's Head of Operations, will be attending OBN BioTuesday: "A Spotlight on the Latest R&D in the Metabolic Disease and Obesity Space" hosted by FTI Consulting in London.
Ash is eager to connect, share insights, and explore new collaborations that advance drug discovery and improve outcomes in metabolic disease and obesity research. Looking forward to meeting you there!
#OBNBioTuesday #Pharmidex #DrugDiscovery #MetabolicDisease #ObesityResearch
We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist
We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. 👩🔬 👨🔬 Welcome to the team, Gabrielle and Mohammed!
At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: ✅ Bitter-tasting APIs ✅ Unpalatable excipients ✅ The success of taste-masking strategies ✅ Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.
